Eli Lilly is acquiring Ajax Therapeutics to advance AJ1-11095, an experimental next-generation JAK2 inhibitor designed to deliver deeper, longer-lasting benefits for patients with myelofibrosis and other blood cancers that do not respond well to existing treatments. “Lilly has long believed in the approach and is excited…
News
The U.S. Food and Drug Administration (FDA) has approved a new once-daily formulation of Jakafi (ruxolitinib), known as Jakafi XR, for adults with intermediate- or high-risk myelofibrosis. Like the original version of Jakafi, which is taken twice daily, Jakafi XR is also FDA-approved to treat certain people…
People with myelofibrosis who had low blood cell counts before starting ruxolitinib had shorter overall survival after treatment, according to a new study. “Cytopenias [low blood cell counts] before the start of ruxolitinib treatment have an unfavorable effect on the outcome and survival of patients with myelofibrosis,” researchers wrote in…
Combining the blood cancer therapy selinexor with Jakafi (ruxolitinib), an oral treatment approved for adults with myelofibrosis, outperformed Jakafi alone in rapidly reducing spleen size and showed promising signs of extending survival. These are the early findings from Karyopharm Therapeutics‘ ongoing global Phase 3 trial, dubbed SENTRY (NCT04562389),…
Recent Posts
- Lilly acquires Ajax to advance next-gen myelofibrosis treatment
- FDA approves once-daily Jakafi XR for some myelofibrosis patients
- What I didn’t understand the first time I researched my myelofibrosis diagnosis
- Low blood cell counts before treatment may signal higher risk in myelofibrosis
- Drug combo outperforms standard myelofibrosis treatment in trial